Tla Targeted Immunotherapies Ab

Almac Sciences (scotland) Limited

Ge Healthcare As

Ith Immune Therapy Holdings Ab

Graham John Cotton

Ola Winqvist

Klaes Golman

Mikkel Jacob Thaning

Robert Ramage

Rolf Servin

Jan Wolber

Jan-Henrik Ardenkjaer-Larsen

Mark Howard

Herbert Baumann

Paul William Armstrong

Mathilde H Lerche

Ian Wilson

Alastair Mackie Hay

David William Anderson

Robert Austin Simms McMordie

Sarah Claire Monique Couturier

Beatrice Maltman

A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

Treating multiple sclerosis

A method for treating a condition associated with metabolic syndrome or for treating adiposis dolorosa (AD) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR1, CCR3, CCR4 or CCR5 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR1, CCR3, CCR4 and CCR5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

Treating conditions associated with metabolic syndrome

A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR5, CXCR1, CXCR2, and/or CCR2 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR5, CXCR1, CXCR2, and/or CCR2 expressing cells from the peripheral blood of the patient or subject. Various companion therapeutic methods and useful binding reagents are also described.

Treating conditions associated with sepsis

A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR1, CCR3, CCR5, CXCR1, CXCR2 and/or CCR7 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR1, CCR3, CCR5, CXCR1, CXCR2 and/or CCR7 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

Treating respiratory conditions

A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR9, CCR1, CCR3 and/or CCR5 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally CCR9, CCR1, CCR3 and/or CCR5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

Treating mental disorders

A method for treating cancer comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or to a Treg receptor immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR7, CCR5, CCR6, CCR8, CXCR4, CXCR7, CCR4, CCR9, CCR10, CXCR3 or CXCR5 or Treg receptor expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

Treating cancer

A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14HLA-DRmonocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample obtained from a subject, wherein high levels of CD14HLA-DRmonocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9, or increased levels of CD14HLA-DRmonocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 compared to control, indicate the presence or progression of inflammatory bowel disease. Similar methods for diagnosing irritable bowel syndrome are also described. Various companion therapeutic methods and useful binding reagents are also described.

Diagnosing and treating inflammatory diseases

The present invention relates to fluorescent dyes based on acridine derivatives and use of such dyes, for example, in biochemical and/or cell based assays. A preferred feature of some of the dyes described is their long fluorescence lifetimes and their use to label biological molecules.

Fluorescent dyes and uses thereof

An apheresis column loaded with a solid support comprises one or more chemokines, in particular biotinylated chemokines, immobilized directly or indirectly on the support, in particular on a support carrying streptavidin. Also disclosed are uses of the column and the support and a method of depleting cells, in particular leukocytes, from the peripheral blood of a person suffering from an inflammatory condition such as Inflammatory Bowel Disease (IBD).

Chemokine containing apheresis column and methods of use

The present invention relates to a series of compounds useful for effecting purification, in particular for use in purification of synthetic peptides and proteins. The compounds of the invention are particularly efficient at securely anchoring peptides or proteins to a surface and allowing the peptide or protein to become uniformly orientated, thus ensuring that substantially all of the peptide or protein is available for molecular binding to a substrate.

Purification tags of synthetic peptides and proteins

A method of ligating two or more molecules, for example, peptides to peptides or peptides to labels is provided. The method may comprise the steps: a) providing a first oligopeptide having a reactive moiety, which is a hydrazine moiety, a hydrazide moiety or an amino-&#xf3;xy moiety b) providing a second oligopeptide having an activated ester moiety, c)allowing the reactive moiety of the first oligopeptide to react with the activated ester moiety of the second oligopeptide to form an oligopeptide product, in which the first and second oligopeptides are linked via a linking moiety having Formula I, II or III. The second oligopeptide may preferably be generated by thiol reagent induced cleavage of an intein fusion protein. The invention further provides labelling and ligation methods in which protein hydrazides are ligated by reaction of the hydrazide moiety with an aldehyde functionality or a ketone functionality.

Ligation method

The invention relates to NMR-based methods comprising hyperpolarised ligands or targets for use in NMR-based assays.

NMR-based methods for detecting ligands, where the ligand or target are hyperpolarized and the NMR-spectrum is compared with a reference spectrum of the ligand or target

Growing community of inventors

Gladsmuir, United Kingdom

Graham John Cotton